Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2008-09-19
2011-10-11
Sang, Hong (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
Reexamination Certificate
active
08034359
ABSTRACT:
The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of a treatment response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. The administration of the immunogenic compositions may be repeated relatively frequently over a relatively long period of time. In embodiments for intradermal or subcutaneous injection, dosages may be adjusted so that injections reproduce a consistent visible delayed inflammatory immune reaction at the successive site or sites of administration.
REFERENCES:
patent: 3928565 (1975-12-01), Homma et al.
patent: 4329452 (1982-05-01), Maruyama
patent: 6348586 (2002-02-01), Chang et al.
patent: 2002/0044948 (2002-04-01), Khleif et al.
patent: 2004/0014661 (2004-01-01), Goetsch et al.
patent: 2005/0070463 (2005-03-01), Libon et al.
patent: 1415655 (2004-05-01), None
patent: WO9526742 (1995-10-01), None
patent: WO0156387 (2001-08-01), None
patent: 0223994 (2002-03-01), None
patent: WO 03/009859 (2003-02-01), None
patent: WO03049751 (2003-06-01), None
patent: WO03049752 (2003-06-01), None
patent: WO03063593 (2003-08-01), None
patent: WO 2005/099750 (2005-10-01), None
patent: WO2005120560 (2005-12-01), None
Jeannin et al., Nature Immunology, 2000, 1(6):502-509.
Assersohn, L. et al., A Randomized Pilot Study of SRL172 (Mycobacterium vaccae) in Patients with Small Cell Lung Cancer (SCLC) Treated with Chemotherapy, Clinical Oncology, 14:23-27 (2002).
Balch, C.M. et al., A randomized prospective trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (stage I), Cancer 49(6):1079-1084 (Mar. 15, 1982).
Hanaue, H. et al., Hemolytic streptococcus preparation OK-432; beneficial adjuvant therapy in recurrent gastric carcinoma, Tokai J Exp Clin Med 12(4):209-214 (Nov. 1987).
Harper-Wynne, C. et al., Addition of SRL 172 to standard chemotherapy in small cell lung cancer (SCLC) improves symptom control, Lung Cancer 47(2):289-290 (Feb. 2005).
Higgins, G. and Pack, G., Virus therapy in the treatment of tumors, Bull Hosp Joint Dis 12:379-382 (1951).
Hrouda D. et al., Immunotherapy of Advanced Prostate Cancer: a Phase I/II Trial Using Mycobacterium Vaccae, British Journal of Urology, vol. 82(4):568-573 (Oct. 1998).
Kassabov, K.T. and Stoychkov, J.N., Inhibition of spontaneous pulmonary metastases of Lewis lung carcinoma by oral treatment with Respivax and Broncho-Vaxom, Cancer Immunol Immunother 33:307-313 (1991).
Kleef, Ralph et al., Endotoxin and Exotoxin Induced Tumor Regression with Special Reference to Coley Toxins: A Survey of the Literature and Possible Immunological Mechanisms, Report to the National Cancer Institute Office of Alternative and Complementary Medicine (Aug. 1997).
Kohmel, K.F. et al., Prior immunization of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients, Eur J Cancer 41:118-125 (2005).
Kohmel, K.F. et al., Treatment of advanced malignant melanoma by a pyrogenic bacterial lysate: a pilot study, Onkologie 14:411-417 (1991).
Li, Z. et al., A clinical study on PA—MSHA vaccine used for adjuvant therapy of lymphoma and lung cancer, Hua Xi Yi Ke Da Xue Xue Bao 31(3):334-337 (Sep. 2000).
MacLean, J. et al., Vaccination strategies for the prevention of cervical cancer. Expert. Rev. Anticancer. Ther. 5(1):97-107 (Feb. 2005).
Mihich, E. and Neter, E., Necrotizing effects ofStaphyloccus aureusextract on mouse sarcoma, Proc Soc Exp Biol Med 106:97-101 (1961).
Myers, J. et al., Combined modality therapy of advanced nodular lymphomas: the role of nonspecific immunotherapy (MBV) as an important determinant of response and survival, Proc Am Soc Clin Oncol 24:56 (1983).
Nauts, H.C. et al., A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man, Acta Med Scand 145 (Suppl. 276):5-103 (1953).
O'Brien, M.E.R. et al., SRL172 (killedMycobacterium vaccae) in patients with advanced non-small-cell lung cancer: phase III results, Anals of Oncology 15:906-914 (2004).
Ochiai, T. et al., Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall endoskeleton. Three-to six-year follow-up of a randomized clinical trial, Cancer Immunol Immunother 14:167-171 (1983).
Ogura, T., Immunotherapy of respectable lung cancer using Nocardia rubra cell wall skeleton, Gan to Kagaku Ryoho 10(2 Pt 2)366-372 (1983).
Ohno, R. et al., Randomized controlled study of chemoimmunotherapy of acute myelogenous leukemia (AML) in adults with Nocardia rubra cell-wall skeleton and irradiated allogeneic AML cells, Cancer 57(8):1483-1488 (Apr. 1986).
Pack, G., Note on the experimental use of rabies vaccine for melanomatosis, Arch Dermatol 62:694-695 (1950).
Paterson, Y. and Maciag, P.C. Listeria-based vaccines for cancer treatment. Curr. Opin. Mol. Ther 7(5):454-460 (Oct. 2005).
Pfahlberg, A. et al., Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study, J Invest Dermatol 119:570-575 (2002).
Smith, R.E. et al., Randomized trial of adjuvant therapy in colon carcinoma: 10-Year results of NSABP protocol C-01, J. NCI 96(15)1128-1132 (2004).
Sur, P. and Dastidar, A., Role of Mycobacterium w as adjuvant treatment of lung cancer (non-small cell lung cancer), J. Indian Med Assoc 101(2):118-120 (Feb. 2003).
Sylvester, R.J. et al., Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients With Superficial Bladder Cancer: A Meta-Analysis of the Published Results of Randomized Clinical Trials, The Journal of Urology 168:1967-1970 (Nov. 2002).
Uyl-De Groot, C.A. et al., Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits, Vaccine 23(17-18):2379-2387 (2005).
Yasumoto, K. and Yamamura, Y., Randomized clinical trial of non-specific immunotherapy with cell-wall skeleton of Nocardia rubra, Biomed Pharmacother 38(1):48-54 (1984).
Bast et al., “Immunostimulants”; Holland-Free Cancer Medicine 5th Edition—NCBI Bookshelf; http://www.ncbi.nlm.nih.gov/bookshelf.br.fcgi?book-cmed&part-A13924; 20 pp (2000).
Likhite, “Rejection of Tumors and Metastases in Fischer 344 Rats Following Intratumor Administration of Killed Corynebacterium Parvum”; Int. J. Cancer 14: 684-690 (1974).
Abel U, Becker N, Angerer R, et al. Common infections in the history of cancer patients and controls. J Cancer Res Clin Oncol. 1991; 117(4):339-344.
Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med. 2002;162(11):1286-1292.
Ajani UA, Ford ES, Mokdad AH. Dietary fiber and c-reactive protein: Findings from National Health and Nutrition Examination Survey Data. 2004;134:1181-5.
Akre K, Ekstrom A, Signorello L et al. Aspirin and risk for gastric cancer: a population-based case-conrol study in Sweden. Br J Cancer 2001;84:965-968.
Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy—review of a new approach. Pharmacol Rev 2003;55:241.
Baer, DJ, Judd JT, Clevidence BA et al. Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: A randomized crossover study. Am J Clin Nutr 20
Bozicevic Field & Francis LLP
Field Bret E.
Foulds Glenn J.
Qu Biologics Inc.
Sang Hong
LandOfFree
Tissue targeted antigenic activation of the immune response... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue targeted antigenic activation of the immune response..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue targeted antigenic activation of the immune response... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4284474